Annual report pursuant to Section 13 and 15(d)

Acquisitions, Investments, and Licenses (Tables)

v2.4.1.9
Acquisitions, Investments, and Licenses (Tables)
12 Months Ended
Dec. 31, 2014
Business Acquisition [Line Items]  
Pro forma disclosure for acquisitions
The following table includes the pro forma results for the years ended December 31, 2013 and 2012 of the combined companies as though the acquisition of OPKO Biologics and OPKO Renal had been completed as of the beginning of the period presented.
 
For the years ended December 31,
(In thousands)
2013
 
2012
Revenues
$
96,530

 
$
53,595

Loss from continuing operations

 
(63,479
)
Net loss
(147,546
)
 
(55,663
)
Net loss attributable to common shareholders
(145,027
)
 
(57,411
)
Basic and diluted loss per share
$
(0.37
)
 
$
(0.15
)
Maximum exposure of unconsolidated investments
The following table reflects the accounting method, carrying value and underlying equity in net assets of our unconsolidated investments as of December 31, 2014:
(in thousands)
 
 
 
 
Investment type
 
Investment Carrying Value
 
Underlying Equity in Net Assets
Equity method investments
 
$
9,400

 
$
30,787

Variable interest entity, equity method
 
981

 

Available for sale investments
 
5,758

 
 
Warrants and options
 
6,314

 
 
Total carrying value of investments
 
$
22,453

 
 
OPKO Renal and OPKO Biologics  
Business Acquisition [Line Items]  
Estimated fair value of the net assets acquired and liabilities assumed in the acquisition of at the date of acquisition
The following table summarizes the purchase price allocation and the fair value of the net assets acquired and liabilities assumed in the acquisitions of OPKO Renal and OPKO Biologics:
(In thousands)
OPKO Renal
 
OPKO Biologics
Current assets (1)
$
1,224

 
$
21,500

Intangible assets:
 
 
 
In-process research and development
191,530

 
590,200

Patents
210

 

Total intangible assets
191,740

 
590,200

Goodwill
2,411

 
139,784

Property, plant and equipment
306

 
1,057

Other assets

 
371

Accounts payable and accrued expenses
(1,069
)
 
(9,866
)
Deferred tax liability

 
(156,403
)
Total purchase price
$
194,612

 
$
586,643

(1) 
Current assets include cash of $0.4 million and $20.5 million related to the OPKO Renal and OPKO Biologics acquisitions, respectively.
SciVac  
Business Acquisition [Line Items]  
Summary of consolidated assets and non-recourse liabilities related to SciVac
The following table represents the consolidated assets and non-recourse liabilities related to SciVac as of December 31, 2014 and December 31, 2013. These assets are owned by, and these liabilities are obligations of, SciVac, not us.
(In thousands)
December 31,
2014
 
December 31,
2013
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
393

 
$
2

Accounts receivable, net
316

 
283

Inventories, net
1,649

 
1,696

Prepaid expenses and other current assets
718

 
218

Total current assets
3,076

 
2,199

Property, plant and equipment, net
1,725

 
1,374

Intangible assets, net
875

 
1,111

Goodwill
1,553

 
1,821

Other assets
384

 
261

Total assets
$
7,613

 
$
6,766

Liabilities
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
445

 
$
1,136

Accrued expenses
4,446

 
6,498

Notes payable
5,189

 
1,537

Total current liabilities
10,080

 
9,171

Other long-term liabilities
2,042

 
1,240

Total liabilities
$
12,122

 
$
10,411